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The Consultative Group on International Agricultural Research. 
(CGIAR) mobilizes the best in agricultural science on behalf of the 
woild’s poor and hungry. Throu.gh its research, the CGIAR promotes ’ 
,sustainable agriculture for food security in developing countries. 
. The CGIAR supports a network of sixteen international agricultural ’ 
research centers, which implement an agreedlupon agenda in’ 
., partnership with national governmental and non-governmental’ 
organizations,, universities, and.private industry.’ The Food and : 
‘:Agriculture Organization (FAO)of the United Nations, the United ‘. . 
Nations Development Programme (UNDP), the United Nations 
Environment Programme.(UNEP), and the world Bank cosponsor tlie ’ 
‘CGIAR. 
’ For more than a‘ quarter century, the.CGI.AR has brought together the 
world’s leading scientists and agricultural‘rksearchers in a unique ’ 
South-North commitment, to reduce poverty.and .hunger in developing 
I countries. This is important because 95 percent of the 90 m illion 
-people born every year live in the poorest countries. Whether 
researching fo,od crops, forestry, livestock, irrigation management, 
aquatic resources, or, policy, the CGIAR focuses on productivity and 
natural resources management -which are emphasized in its s;ervices 
to’agricultural research systems in developing countries. CGIAR’ 
activities have contributed to global food security, helping to keep the 
environment.healthy and farm ing sustainable. . 
. 
The fifty-eight members that support the CGTAR include developing 
and developed countries, economies in transition,. private foundations, 
‘and international.and regional organizations. -Developing-countr$ . ’ 
participation has doubled in recent’years. All twenty-two m ,embers of 
the OECD (Organisation.for Economic Co-operation and Develop- . 
ment) Development Assistance Committee belong to the CGIAR. - 
‘_ Isrtiail Serageldin, Vice President for Special P-rograms at the World 
Bank, serves as the CGIAR Chairman. ‘. . 
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Sir John Crawford ( 19 lo- 1984) was a distinguished 
Australian civil servant, educator, and agriculturalist who 
was one of the founders of the Consultative Group on 
International Agricultural Research and the first Chair of the 
CGIAR’s Technical Advisory Committee. The Sir John 
Crawford Memorial Lecture has been sponsored by the 
Australian Government since 1985 in his honor. 
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S ir John Crawford functioned at various stages of his career as a professional economist, a senior civil servant, and an academic leader. You honor him for his international role 
as a key architect of the CGIAR. Those of us who are 
compatriots value him for his many contributions during a time 
of optimism and rapid development in our country. His 
influence in Australia was enormous. Crawford was the first 
Direc.tor of the Research School of Pacific Studies at the newly 
formed Australian National University (ANU), an academic 
center that has played a considerable role in fostering both public 
policy and interactions in the South East Asian region. He then 
led the university as Vice Chancellor, and finally assumed the 
more ceremonial role of Chancellor. In all, he served the ANU 
for over 20 years. I never met him, though I was a member of 
the university at times when he was a senior figure. The work 
with Rolf Zinkernagel that was recognized by the 1996 Nobel 
Prize for Physiology or Medicine was done at the ANU, and was 
initiated during the time that Crawford was Vice Chancellor. 
Quoting from a recent history’ of the ANU, “he was short, 
unassuming in manner but vastly impressive for his depth of 
knowledge, understanding of issues and diplomatic skills”. He is 
remembered in Australia as one of the seven dwarfs, a group of 
senior economists and civil servants of the 1950s and 1960s who 
shared the characteristic of being both extremely able and 
vertically challenged. Gabrielle Persley, who worked with 
Crawford, tells me that he never held a meeting until he knew 
what the outcome would be, and would gently steer the 
committee to the decision that he had made earlier. Crawford 
belonged to an era when public policy in the western demo- 
cracies was more oriented to the common good, a time that many 
of us may look back to with a sense of nostalgia. I wonder what 
he would make of political agendas and economic strategies that 
emphasize personal greed as the most laudable of human 
characteristics. 
All of us in this room are acutely aware of the importance of the 
CGIAR and are, I suspect, more than a little intimidated by the 
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problems that this organization is trying to address. There can 
be no doubt in the mind of anyone who has spent time in the 
developing world that the dismal predictions that Malthus made 
more than 170 years ago are rapidly coming to fruition. All the 
major Scientific Academies share this conclusion. Uncontrolled 
population growth is leading to increased social turmoil, 
degradation of the environment and the appalling prospect of 
periodic starvation at levels that will make current disasters seem 
like minor eventsI. This proceeds against a depressing backdrop 
of cultural and political agendas that do everything possible to 
deny the reality of what is happening and can function to 
diminish the meager resources currently available to address 
such issues. What is even more frightening is the sense that, as 
the pressures increase, the inevitable result will be a rise in 
reactionary politics and terrorism that will tend to make any 
rational response even more difficult. There will be no safe 
place. The CGIAR tries to deal with some of the consequences, 
though it is inherently unable to address the causes. 
My association with the CGIAR stems from the six years (1986- 
1992) that I spent as Member, and latterly Chair of the Program 
Committee, of the Board of the International Laboratory for 
Research in Animal Diseases (ILRAD) in Nairobi, Kenya. As 
you know, ILRAD was combined with its sister field 
organization, International Livestock Centre for Africa (ILCA), 
some years back to constitute ILRI, the International Livestock 
Research Institute. Learning the acronyms is one of the first 
challenges for anyone who becomes involved in the international 
arena! It took me two years! The appointment as an ILRAD 
Board Member reflected my early training in veterinary science 
and a common interest in immunity to infection. The first nine 
years of my career were spent working in veterinary research 
institutes on diseases of domestic animals, while I switched 
some 27 years back to studying similar processes in laboratory 
mice and was thus transformed into a basic medical scientist. In 
my case, M.D. is “mouse doctor.” The current reality is that all 
science is convergent, and the categories do not much matter. 
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The molecular genetic approaches that are used in biomedicine 
and animal and plant agriculture are essentially identical, with 
the latter activity benefiting from the massive basic biomedical 
research enterprise. You must forgive me for drawing examples 
as I talk from the animal side of things, but this is my area of 
expertise. 
What does a laboratory rat like me have to say that could be of 
any value to international shakers and movers like you? The 
best that I can offer is that after 36 years in the game, I have 
some familiarity with the way that science operates. The 
mandate of the CGIAR is to seek solutions to the related 
problems of hunger, poverty and environmental degradation in 
the broadest sense through the application of science and 
technology-. The scope of the activities and the magnitude of the 
problems are very clearly stated in the Report of the 3rd CGIAR 
System Review that is being presented at this meetingz. 
Economists, social scientists and facilitators in the Crawford 
tradition will obviously play enormously important roles. 
However, it is essential that both the funding agencies and the 
organization itself should also have the realities of science in 
perspective and understand something of the way that innovative 
scientists operate. 
Make no mistake: if the CGIAR is to succeed in the mammoth 
task that it has undertaken, it is essential to promote environ- 
ments which foster the mind jumps that provide novel solutions. 
A marvelous example of such innovation from the economics 
side is the Grameen Bank of Bangladesh, which was reviewed 
recently by Muhammad Yunus3 for the readers of Science, a 
journal that publishes many of the cutting edge findings in 
laboratory-based research. I mention this because the fact that 
the Editors of Science are seeking such commentary reflects that 
many basic scientists are now taking a keen interest in real 
problems and their solutions. This move towards the practical is, 
I think, a direct consequence of the molecular biologyibiotech- 
nology revolution. 
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The first point that we must deal with as a research agency is that 
the level of government support for both national agricultural 
research programs and for the international scene is not high and 
is, in many cases, falling. Next year’s annual budget for the US 
National Institutes of Health is expected to be in excess of $US 
15 billion, representing a 14 percent increase over 1997- 1998. 
The research budget for the USDA is about $1.5 billion, and for 
the whole of the CGIAR is less than $400 million. The American 
Howard Hughes Medical Institute spends in excess of $300 
million, while the British Wellcome Foundation allocates &300 
million to the biomedical area. My own institution, St. Jude 
Children’s Research Hospital has an annual research budget in 
excess of $60 million for non-clinical, basic science. The US 
allocation for research on AIDS alone is approximately $1.5 
billion, with 10 percent of that going towards the development of 
an AIDS vaccine. 
Vaccination has been very much the focus of the international 
biomedical research community. Given the enormous difficulty 
of achieving widespread behavioral modification, it seems very 
obvious that the only way to deal with the increasingly disas- 
trous AIDS pandemic in the poorer countries is to develop an 
effective and reasonably inexpensive vaccine. Those of us who 
work on viral immunity believe that such a product can be made, 
though there is currently no obvious strategy for success and the 
effort may take many years. 
The Children’s Vaccine Initiative (CVI), which was initiated in 
1996, is seeking to give all the world’s children the available 
childhood vaccines. Smallpox has been eliminated from the 
world 200 years after Edward Jenner introduced vaccination to 
the west. Fortunately, the lead-time from innovation to practical 
solution is now somewhat shorter. It looks likely that polio- 
myelitis will be gone by 2002 and the global eradication of 
measles now seems also to be a possibility. Paradoxically, the 
main threat to this initiative is in the industrialized world, where 
vocal minorities that have never seen these diseases are seeking 
to block all government mandated vaccination programs. 
Anyone who is not frightened by the rise of the irrational in the 
so-called advanced countries should look up “Vaccination” on 
the Internet. The experience is almost as terrifying as listening 
to talk-back radio! 
The CVI is being pursued as an exercise in compassion and 
common morality, involving a spectrum of organizations ranging 
from WHO to Rotary, which has paid for much of the vaccine. 
The underlying assumption for those who think in terms of 
stabilizing the global population is that people will act to reduce 
family size if there is a reasonable assurance that their children 
will survive. However, the issue is much more complex than 
that, as the move to have less children also requires the 
empowerment of women and other behavioral changes that are 
deeply threatening to elements that seem to have increasing 
force in some traditional cultures. 
The CGIAR cannot, of course, afford to be drawn into contro- 
versies surrounding these broader social issues. The focus must 
be on strategies that involve the environmentally sensitive 
application of the science and technology of food production and 
supply2. Such issues are, in most instances, likely to be less 
emotive in the political sense. Battles concerning where and 
when the application of genetic engineering approaches will be 
applied to animal and plant agriculture are being fought out first 
in the donor countries of the industrialized world. A powerful 
force is the commercial interests that stand to make a profit. 
Those of us who have a broad profile are doing our best to 
ensure that public perceptions and legislation do not inhibit the 
sensible and careful application of the new technologies. 
In particular, we need to convince those who are environ- 
mentally conscious of the possibilities for reducing the use of 
both chemical fertilizers and insecticides by the appropriate 
engineering of animals and plants. It is ironic that we are 
already injecting people with large doses of DNA in experi- 
mental viral vaccines made from human pathogens, while others 
are agonizing about the infinitesimal possibility that a disease 
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resistance gene that has been engineered into a plant will 
somehow enter human cells and cause cancer. Such gene 
transfer is not that easy. Most of us have been eating vegetables 
all our lives, but have not turned green and started to make 
chlorophyll! Scientists are increasingly aware that they cannot 
just squirrel away happily in their laboratories, but must also 
accept a broader responsibility to discuss, to educate and to 
dispel ill-founded myths and fears. 
Some technologies that are very much in the CGIAR ballpark 
are ripe for application, particularly in the plant sciences. 
Problems where the solution seems obvious may be rapidly 
addressed by the direct application of established genetic 
engineering approaches. Such efforts are appropriate targets for 
short-term, directed funding mechanisms. Other problems are 
much more long-term and difficult. 
The two cattle diseases that have been the consistent laboratory 
focus of ILRAD, and then ILRI, for more than 20 years are 
Trypanosomiasis and East Coast fever (ECF). Biologically, 
Trypanosomiasis is at least as complex and difficult to deal with 
as human AIDS. The cause of ECF is a protozoan parasite, 
Theileriaparva, that has a life cycle in many senses comparable 
to that of the Plasmodium species responsible for human 
malaria. The difference is that T. parva grows in the lympho- 
cytes, or white blood cells, while Plasmodium is in the erythroid, 
or red cell lineage. Candidate vaccines for both these diseases 
are at roughly equivalent stages of development, though the 
dollars spent on Theileria research must be 10 percent of those 
available for malaria. The CGIAR does get value for money! 
The medical community accepts that malaria is an enormously 
difficult problem. One of the reasons that I work in medical 
research is that there has been a tendency to assume that 
veterinary diseases can be dealt with by quick, simple and naive 
approaches, a perception that is patently absurd. 
The point is that research on a disease as complex as ECF needs 
to be open and imaginative, looking for novel insights and 
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exploring different avenues. This is why it is so important that a 
substantial component of the budget for each of the CGIAR 
Centers should be flexible and available for the pursuit of long- 
term goals, with quality control depending on regular, scientific 
review. Holding scientists to an exclusive focus on immediate, 
practical outcomes ensures mediocrity and the rapid defection of 
talented investigators. If the American research enterprise over 
the past 50 years had followed “short term solution” models we 
would still be paying engineers to build better iron lungs and 
cannon builders to put a man on the moon. Innovative science is 
a great deal more than engineering, whether it be mechanical, 
electrical or genetic, though there is always a stage where the 
engineers and managers take over to see the product through to 
production and distribution. 
Both ECF and Trypanosomiasis can be used to illustrate another 
point that concerns anyone who looks at the international 
agricultural research enterprise. The question is: “Should the 
CGIAR Centers in the developing world focus only on end- 
stage, practical objectives, while the more imaginative and 
innovative work is left to Universities and Research Institutes in 
the industrialized countries?” I know science and I know 
scientists, and have absolutely no problem in telling you that this 
would be a fatal mistake. 
The primary requirement for any viable research enterprise is 
that the scientific staff must be of top quality. First rate 
scientists will tolerate many minor annoyances, but they will not 
accept a situation where it is impossible to explore and to test 
ideas. The best young investigators will take on the challenge of 
studying a complex disease problem like Trypanosomiasis, but 
they will not tolerate a short leash and being told what to do. Put 
such people back in an academic environment where they do not 
see cattle with Trypanosomiasis and there is a real risk that they 
will lose focus and go of on some intellectually satisfying, but 
less practically-oriented direction. Such research is readily 
funded by biomedical research grants, and it is easy to forget 
quickly about the tough and in some senses unglamorous 
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problems that are being tackled by the CGIAR. There is no 
Nobel Prize for agriculture! 
The costs and regulatory constraints on maintaining large 
‘domestic animals infected with exotic diseases like Trypano- 
somiasis or ECF in Europe or North America are now 
prohibitive. Such studies must be done in the countries where 
the problem exists. Some aspects of ECF immunity can, for 
example, be analyzed by putting lymphocytes on a plane in 
Nairobi and sending them to Utrecht or to M iami. However 
there is a great deal of work that needs to be done either close to 
the experimental animal, or directly in the field. A prime 
example is the marker/segregation analysis aimed at finding 
genes conferring resistance to Trypanosomiasis that has been in 
progress for some years at ILRI. Identification of these genes 
could lead to their rapid dissemination through the African herd, 
either by more traditional methods such as artificial insemination 
or by advanced genetic engineering approaches. Such large- 
scale cattle breeding experiments that require challenge with the 
infecting organism are only possible in Africa. 
Having said this, there is a good case for encouraging the 
development of funding mechanisms that facilitate research 
enterprises based both in a major European or American 
university and in a CGIAR Center. The exchange of scientists, 
particularly at more junior levels, and the ready access to the 
extensive technological resources that exist only in the 
industrialized countries has the potential to move programs 
along much more effectively. There is also the likelihood of 
multiplier effects, as scientists discussing their work in an open 
academic environment interest others in the problem. Living for 
even a few months in a developing country is also a great 
experience for young scientists, and increases the national pool 
of talented and knowledgeable people that can be drawn on later 
to assist in formulating and applying AID agendas and the like. 
I benefited enormously from the time I spent on the ILRAD 
Board and learned a great deal, especially, from my African 
colleagues. It was a civilizing experience for me. 
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A further major, though somewhat understated, role of the 
CGIAR Centers is that they provide a focus for training local 
scientists. The value of such experience can be greatly enhanced 
if some time is also spent in an affiliated institution in the 
Northern Hemisphere. Modern molecular biology does not need 
enormously sophisticated laboratories and is, in fact, being 
pursued very effectively in a number of countries that none of us 
would think of as being at the forefront of science. It is 
important to have sophisticated, in-country expertise at the level 
of, for example, the National Agricultural Research Services, 
both to pursue scientific applications and to provide sound 
advice to governments. If the ILRAD/ILCA/ILRI example is 
typical, the CGIAR has been doing an excellent job in this 
regard. We calculated earlier this year that this small (by 
biomedical research standards) operation has trained over 300 
young scientists, including 55 from Ethiopia and 70 from Kenya. 
There are currently 55 graduate students at ILRI. 
I have tried to use this lecture to convey some sense of the 
realities of the scientific culture. Progress in any scientific 
endeavor will only be as good as the people involved. It is 
sometimes difficult for those who work in oligarchies to 
understand that first class research investigators do not think like 
civil servants, will not be micro-managed, and are not inter- 
changeable, disposable products. Their ultimate realities are the 
difficult scientific problems that they are addressing, not the 
perceptions of a senior administrator or a political master. 
Active scientists can often be a pain in the neck for 
administrators! 
There is nothing that competitive scientists loathe more than 
bureaucratic structures, filling in forms and the perception that 
managers are proliferating at the expense of the research 
programs. This needs to be understood if the CGIAR is to retain 
and to continue recruiting those with real ability, both as 
scientific investigators within the various Centers and as 
collaborators at major institutions in the industrialized world. 
The latter type of person is generally well funded, and tends to 
12 
have little time for either administrative trivia or for unrealistic 
expectations of “quick-fix” solutions. Though there are many 
people with scientific credentials, the pool of outstanding people 
is very limited. 
The almost exponential growth of the biomedical research 
enterprise in the USA means that the competition for talent is 
enormous. Modern molecular medicine is already absorbing 
skilled people with basic training in the molecular biology 
aspects of animal and plant agriculture. I have several young 
colleagues at St. Jude Hospital who did their doctoral studies in 
the plant sciences or in veterinary medicine, but have switched to 
basic cancer research and cell biology. 
The optimal way for donors to promote a situation where there 
can continue to be real innovation within the CGIAR structure is 
to provide a good measure of funding to support the type of 
sustained effort that is likely to lead to long-term solutions. The 
review of the science and the progress towards stated goals is 
best left to the excellent mechanisms that the CGIAR has in 
place. Providing answers to the linked problems of poverty and 
hunger2 requires that the Centers should not be forced to focus 
most of their efforts on readily achieved, but inherently limited, 
short-term goals. Flexibility and freedom of action are 
fundamental to achieving rapid scientific progress. 
1. Foster, S.G. and Varghese, M.M. 1996. The Making of the 
Australian National University. Allen and Unwin, Sydney. 
2. Strong, M. et al. Shaping the CGIAR ‘s Future, CGIAR System 
Review Report, Document No. ICW/98/06, September 30, 1998. 
3. Yunus, M. 1998. Alleviating Poverty through Technology. 
Science 282, 409-4 IO. 
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